本帖最后由 老马 于 2012-1-13 21:20 编辑
9 \! p" t1 b' U5 P9 ]; n
; Q% ]2 x9 n, K7 s C; Z爱必妥和阿瓦斯丁的比较
8 q# M+ K, Z" }" v. y' I
A) L9 Z/ h$ Q- Z; ]# x5 F! nhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
1 p1 n$ k3 J; Q, l1 E
6 G3 p" k6 d3 ^
3 M) ]* u# y+ d' h6 n! t2 ]http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
7 h, w$ s9 q" v9 w5 s( s================================================== Z2 E# [+ ~/ M! P1 P- Q4 M6 {
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
2 o5 i1 \% b6 _9 H! S* g& u; lPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
4 J- K& O- \# [0 q1 c, U; M. _Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
5 W1 F7 [; S. L
|
显身卡
